28 terminated. 28 Phase 1, 19 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 28 | Terminated 28 |
| Phase 2 | 19 | Terminated 19 |
Follow Retinal Degeneration: new trials by email Literature Review of Retinal Degeneration trials Research Report on Retinal Degeneration
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Investigate Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Immunogenicity of RO7669330 in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD) RO7669330, Syfovre™, Izervay™ - Geographic Atrophy, Age-related Macular Degeneration | Phase 1 | Terminated | Hoffmann-La Roche | 27 | 2025-07-16 | 2026-08-10 |
| Dose Escalation Study to Evaluate the Safety/Tolerability and Efficacy of EA-2353 in Subjects With Retinitis Pigmentosa EA-2353 - Retinitis Pigmentosa, Retinitis Pigmentosa Syndrome | Phase 1 / Phase 2 | Terminated | Endogena Therapeutics, Inc | 14 | 2022-06-02 | 2024-10-15 |
| Safety and Bioactivity of AXT107 in Subjects With Neovascular Age-Related Macular Degeneration AXT107 0.1 mg, AXT107 0.25 mg, AXT107 0.5 mg - Neovascular Age-Related Macular Degeneration (nAMD) | Phase 1 / Phase 2 | Terminated | AsclepiX Therapeutics, Inc. | 3 | 2021-02-01 | 2024-03-22 |
| Safety and Bioactivity of AXT107 in Subjects With Diabetic Macular Edema AXT107 0.1 mg, AXT107 0.25 mg, AXT107 0.5 mg - Diabetic Macular Edema (DME) | Phase 1 / Phase 2 | Terminated | AsclepiX Therapeutics, Inc. | 6 | 2020-12-10 | 2024-03-22 |
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GSK2798745 in Participants With Diabetic Macular Edema GSK2798745 - Macular Edema | Phase 1 | Terminated | GlaxoSmithKline | 16 | 2020-09-07 | 2024-11-08 |
| Oral Hydroxychloroquine (HCQ) for Retinitis Pigmentosa Caused by P23H- Rhodopsin (RHO) Hydroxychloroquine lower dose, Hydroxychloroquine higher dose - Retinitis Pigmentosa | Phase 1 / Phase 2 | Terminated | University of Michigan | 8 | 2020-02-25 | 2024-10-26 |
| A Study to Test How Well Different Doses of BI 754132 Are Tolerated in Patients With an Advanced Form of Age-related Macular Degeneration Called Geographic Atrophy BI 754132 - Macular Degeneration | Phase 1 | Terminated | Boehringer Ingelheim | 18 | 2019-07-26 | 2023-09-15 |
| Treatment of Macular Edema After Cataract Surgery with Subconjunctival Aflibercept Aflibercept - Irvine-Gass Syndrome | Phase 1 | Terminated | Tufts Medical Center | 1 | 2019-02-22 | 2024-10-15 |
| FOCUS: A Phase I/II First in Human Study to Evaluate the Safety and Efficacy of GT005 Administered in Subjects With Dry AMD GT005, GT005 / Device: Orbit™ Subretinal Delivery System - Dry Age-related Macular Degeneration, Macular Degeneration | Phase 1 / Phase 2 | Terminated | Gyroscope Therapeutics Limited | 56 | 2018-12-17 | 2026-01-28 |
| Safety and Efficacy Study in Patients With Retinitis Pigmentosa Due to Mutations in PDE6B Gene AAV2/5-hPDE6B - Retinitis Pigmentosa | Phase 1 / Phase 2 | Terminated | eyeDNA Therapeutics | 19 | 2017-11-06 | 2025-12-18 |
| Safety Tolerability and Efficacy of Intravitreal LMG324 in the Treatment of Neovascular Age-Related Macular Degeneration LMG324, Ranibizumab 0.5 mg, Sham - Age-related Macular Degeneration (AMD) | Phase 1 / Phase 2 | Terminated | Alcon Research | 25 | 2015-07-22 | 2019-06-05 |
| Open-label, Multli-center, Phase 1b/2a Clinical Trial Designed to Evaluate the Safety and Efficacy of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution in Patients With Macular Edema Dexamethasone Phosphate Ophthalmic - Macular Edema | Phase 1 / Phase 2 | Terminated | Eyegate Pharmaceuticals, Inc. | 25 | 2015-07-01 | 2016-08-03 |
| Intravitreal Celecoxib for Chronic Uveitis Intravitreal Celecoxib - Inflammation | Phase 1 | Terminated | Vanderbilt University | 4 | 2015-06-01 | 2017-02-23 |
| Interferon Gamma-1b Administered Topically for Macular Edema/Intraretinal Schisis Cysts in Rod-Cone Dystrophy (RCD) and Enhanced S-Cone Syndrome (ESCS) Interferon gamma-1b - Inherited Ophthalmic Diseases, Inherited Retinal Degeneration | Phase 1 / Phase 2 | Terminated | National Eye Institute (NEI) | 4 | 2015-01-14 | 2019-08-13 |
| Study of the Intravitreal Implantation of NT-503-3 Encapsulated Cell Technology (ECT) for the Treatment of Recurrent Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD) NT-503-3 ECT implantation, Eylea® injected intravitreally administered every 8 weeks - Macular Degeneration | Phase 1 / Phase 2 | Terminated | Neurotech Pharmaceuticals | 42 | 2014-09-01 | 2022-07-18 |
| Study of SAR421869 in Participants With Retinitis Pigmentosa Associated With Usher Syndrome Type 1B SAR421869 - Usher Syndrome, Retinitis Pigmentosa | Phase 1 / Phase 2 | Terminated | Sanofi | 9 | 2012-03-26 | 2022-04-28 |
| Phase I/IIA Study of SAR422459 in Participants With Stargardt's Macular Degeneration SAR422459 - Stargardt's Disease | Phase 1 / Phase 2 | Terminated | Sanofi | 27 | 2011-06-08 | 2022-04-14 |
| Treatment of Non-infectious Intermediate and Posterior Uveitis Associated Macular Edema With Intravitreal Methotrexate Methotrexate - Non-infectious Intermediate and Posterior Uveitis | Phase 1 / Phase 2 | Terminated | National Eye Institute (NEI) | 2 | 2011-02-01 | 2019-03-27 |
| Microplasmin Intravitreal Administration in Participants With Uveitic Macular Edema Microplasmin - Uveitis | Phase 1 / Phase 2 | Terminated | National Institutes of Health Clinical Center (CC) | 2 | 2011-01-01 | 2018-07-31 |
| A Study of Intravitreal Injections of 2.0mg Ranibizumab in Subjects With Chronic Fluid On OCT Post Multiple Injections With Ranibizumab (Super-dose Anti-VEgf SAVE Trial) Ranibizumab - Age Related Macular Degeneration, Choroidal Neovascular Membrane | Phase 1 / Phase 2 | Terminated | David M. Brown, M.D. | 88 | 2009-12-01 | 2017-01-02 |
Showing 20 of 28. Sign in to see all of them.
Macular Degeneration (11) · Macular Edema (11) · Eye Diseases (6) · Retinal Diseases (5) · Retinitis Pigmentosa (5) · Choroidal Neovascularization (2) · Geographic Atrophy (2) · Uveitis (2) · Anetoderma (1) · Cone-Rod Dystrophies (1) · Diabetes Mellitus (1) · Diabetic Retinopathy (1) · Enhanced S-Cone Syndrome (1) · Eye Diseases, Hereditary (1)
Retinal Diseases (23) · Eye Diseases (22) · Macular Degeneration (12) · Eye Diseases, Hereditary (9) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (7) · Genetic Diseases, Inborn (7) · Pathological Conditions, Signs and Symptoms (6) · Retinal Dystrophies (5) · Uveal Diseases (4) · Pathologic Processes (3) · Signs and Symptoms (3) · Cardiovascular Diseases (2) · Choroid Diseases (2) · Metaplasia (2)
AXT107 (2) · Ranibizumab (2) · pegaptanib (2) · Anti-Inflammatory Agents, Non-Steroidal (1) · Celecoxib (1) · GSK2798745 (1) · Hydroxychloroquine (1) · Methotrexate (1) · Photochemotherapy (1) · Sirolimus (1) · Talaporfin (1) · aflibercept (1) · ecallantide (1) · interferon gamma-1b (1) · microplasmin (1)
AsclepiX Therapeutics, Inc. (2) · Johns Hopkins University (2) · National Eye Institute (NEI) (2) · Sanofi (2) · Alcon Research (1) · Boehringer Ingelheim (1) · Centocor, Inc. (1) · David M. Brown, M.D. (1) · Endogena Therapeutics, Inc (1) · Eyegate Pharmaceuticals, Inc. (1) · Fovea Pharmaceuticals SA (1) · GlaxoSmithKline (1) · Gyroscope Therapeutics Limited (1) · Hoffmann-La Roche (1) · Light Sciences LLC (1)
United States (25) · France (4) · United Kingdom (3) · Australia (2) · Israel (1) · Netherlands (1) · New Zealand (1)
Amir Shojaei, PhD (2) · Alain Gaudric, MD (1) · Charles Johnson, MB, ChB (1) · David M Brown, MD (1) · David Zacks, MD (1) · Diana V. Do, MD (1) · Elias Reichel, MD (1) · Gary Krasner, PhD (1) · Hatice N Sen, M.D. (1) · Hatice Nida Sen, MD, MHSc (1)
PMID 30194931, PMID 22828504, PMID 24705452, PMID 26857842, PMID 27730010, PMID 30646425, PMID 33750925
2014 (1), 2016 (1), 2018 (1)